PE20090605A1 - Composiciones de fenilalanina amoniaco-liasa procariotica y metodos del tratamiento del cancer usando composiciones de la misma - Google Patents
Composiciones de fenilalanina amoniaco-liasa procariotica y metodos del tratamiento del cancer usando composiciones de la mismaInfo
- Publication number
- PE20090605A1 PE20090605A1 PE2008001395A PE2008001395A PE20090605A1 PE 20090605 A1 PE20090605 A1 PE 20090605A1 PE 2008001395 A PE2008001395 A PE 2008001395A PE 2008001395 A PE2008001395 A PE 2008001395A PE 20090605 A1 PE20090605 A1 PE 20090605A1
- Authority
- PE
- Peru
- Prior art keywords
- compositions
- procariotica
- phenylalanine
- cancer
- treatment
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical group N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 title 2
- 229910021529 ammonia Inorganic materials 0.000 title 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 abstract 2
- 229920001223 polyethylene glycol Polymers 0.000 abstract 2
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 abstract 1
- 239000005711 Benzoic acid Substances 0.000 abstract 1
- 239000002202 Polyethylene glycol Substances 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 235000010233 benzoic acid Nutrition 0.000 abstract 1
- 230000003197 catalytic effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/51—Lyases (4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
REFERIDA A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) UNA VARIANTE DE FENILALANINA AMINOLIASA (PAL) PROCARIOTICA TAL COMO ANABAENA VARIABILIS PAL (avPAL) DONDE EN LAS POSICIONES 64, 318, 503 Y 565 SE HAN SUSTITUIDO CON RESIDUO DE SERINA; ADEMAS COMPRENDE POLIETILENGLICOL, DONDE LA PROPORACION avPAL:PEG ES DE 1:3; B) UN PORTADOR SELECCIONADO DE L-FENILALANINA, ACIDO TRANS-CINAMICO, ACIDO BENZOICO, ENTRE OTROS. DICHA COMPOSICION MEJORA LA ACTIVIDAD CATALITICA Y/O ESTABILIDAD DE PAL PROCARIOTICA EN EL TRATAMIENTO DEL CANCER
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6612507P | 2007-08-17 | 2007-08-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20090605A1 true PE20090605A1 (es) | 2009-05-16 |
Family
ID=40363135
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2008001395A PE20090605A1 (es) | 2007-08-17 | 2008-08-15 | Composiciones de fenilalanina amoniaco-liasa procariotica y metodos del tratamiento del cancer usando composiciones de la misma |
Country Status (23)
Country | Link |
---|---|
US (4) | US7537923B2 (es) |
EP (1) | EP2175875B1 (es) |
JP (1) | JP5584120B2 (es) |
CN (1) | CN101803492B (es) |
AR (2) | AR067972A1 (es) |
AU (1) | AU2008289549B2 (es) |
BR (2) | BR122018072594B8 (es) |
CA (1) | CA2687028C (es) |
CL (1) | CL2008002390A1 (es) |
CY (1) | CY1118222T1 (es) |
DK (1) | DK2175875T3 (es) |
ES (1) | ES2602618T3 (es) |
HR (1) | HRP20161474T1 (es) |
HU (1) | HUE029510T4 (es) |
LT (1) | LT2175875T (es) |
MX (1) | MX2009012261A (es) |
PE (1) | PE20090605A1 (es) |
PL (1) | PL2175875T3 (es) |
PT (1) | PT2175875T (es) |
RU (2) | RU2009141987A (es) |
SI (1) | SI2175875T1 (es) |
TW (1) | TWI418787B (es) |
WO (1) | WO2009025760A2 (es) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7534595B2 (en) * | 2006-06-12 | 2009-05-19 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof |
US7537923B2 (en) * | 2007-08-17 | 2009-05-26 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof |
EP3381445B1 (en) * | 2007-11-15 | 2023-10-25 | Amgen Inc. | Aqueous formulation of antibody stablised by antioxidants for parenteral administration |
WO2010014225A2 (en) | 2008-07-30 | 2010-02-04 | Biomarin Pharmaceutical Inc. | Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase |
WO2011078667A2 (en) | 2009-12-22 | 2011-06-30 | Dsm Ip Assets B.V. | Method of finding a biocatalyst having ammonia lyase activity |
PT3025728T (pt) * | 2010-02-04 | 2018-11-05 | Biomarin Pharm Inc | Método para purificar variantes procarióticas de fenilalanina amónia-liase |
WO2012075173A2 (en) | 2010-12-01 | 2012-06-07 | Board Of Regents The University Of Texas System | Compositions and method for deimmunization of proteins |
AU2013295621A1 (en) * | 2012-07-27 | 2015-03-12 | University Of North Texas | Genetically modified probiotic for the treatment of phenylketonuria (PKU) disease |
DK2986722T3 (da) * | 2013-04-18 | 2019-05-13 | Codexis Inc | Manipulerede phenylalaninammoniak-lyasepolypeptider |
CA2930665A1 (en) | 2013-11-18 | 2015-05-21 | Rubius Therapeutics, Inc. | Synthetic membrane-receiver complexes |
CN106456744A (zh) | 2014-04-01 | 2017-02-22 | 鲁比厄斯治疗法股份有限公司 | 用于免疫调节的方法和组合物 |
EP3928787A1 (en) | 2014-04-16 | 2021-12-29 | Codexis, Inc. | Engineered tyrosine ammonia lyase |
EP4005590A1 (en) | 2014-04-29 | 2022-06-01 | Bio-Cancer Treatment International Ltd. | Methods and compositions for modulating the immune system with arginase i |
WO2016008886A1 (en) * | 2014-07-14 | 2016-01-21 | Danmarks Tekniske Universitet | Processes for the production of hydroxycinnamic acids using polypeptides having tyrosine ammonia lyase activity |
KR20220123342A (ko) | 2014-12-22 | 2022-09-06 | 코덱시스, 인코포레이티드 | 인간 알파-갈락토시다제 변이체 |
SG11201811603WA (en) | 2016-07-26 | 2019-02-27 | Biomarin Pharm Inc | Novel adeno-associated virus capsid proteins |
IT201600086488A1 (it) * | 2016-08-22 | 2018-02-22 | St Microelectronics Srl | Dispositivo a semiconduttore e corrispondente procedimento |
CN110573175A (zh) | 2017-02-13 | 2019-12-13 | 科德克希思公司 | 工程化苯丙氨酸氨裂合酶多肽 |
US11739345B2 (en) | 2018-05-09 | 2023-08-29 | Biomarin Pharmaceutical Inc. | Methods of treating phenylketonuria |
TW202005978A (zh) | 2018-05-14 | 2020-02-01 | 美商拜奧馬林製藥公司 | 新穎肝靶向腺相關病毒載體 |
CA3102968A1 (en) | 2018-06-12 | 2019-12-19 | Codexis, Inc. | Engineered tyrosine ammonia lyase |
WO2020123286A1 (en) | 2018-12-14 | 2020-06-18 | Codexis, Inc. | Engineered tyrosine ammonia lyase |
CA3123598A1 (en) | 2018-12-20 | 2020-06-25 | Codexis, Inc. | Human alpha-galactosidase variants |
US11987823B2 (en) | 2019-08-30 | 2024-05-21 | Societe Des Produits Nestle S.A. | Engineered lipase variants |
IL294082A (en) | 2019-12-20 | 2022-08-01 | Codexis Inc | Transgenic variants of acid alpha-glycosidase |
AR122409A1 (es) | 2020-04-03 | 2022-09-07 | Biomarin Pharm Inc | Tratamiento de la fenilcetonuria con aav y formulaciones terapéuticas |
US11959108B2 (en) | 2020-08-28 | 2024-04-16 | Codexis, Inc. | Engineered protease variants |
BR112023003643A2 (pt) | 2020-08-28 | 2023-03-28 | Codexis Inc | Amilase recombinante, composição, sequência de polinucleotídeo recombinante, vetor de expressão, célula hospedeira, métodos para produzir uma amilase recombinante e para tratar e/ou prevenir os sintomas de insuficiência pancreática, composição farmacêutica para o tratamento de insuficiência pancreática, e, uso |
WO2022245924A1 (en) | 2021-05-19 | 2022-11-24 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating adolescent subjects |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4252822A (en) | 1979-12-26 | 1981-02-24 | Children's Hospital Medical Center | Method for treating phenylketonuria |
US4562151A (en) | 1983-09-06 | 1985-12-31 | Monsanto Company | Stabilization of L-phenylalanine ammonia-lyase enzyme |
US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
US5166322A (en) | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
US5766897A (en) | 1990-06-21 | 1998-06-16 | Incyte Pharmaceuticals, Inc. | Cysteine-pegylated proteins |
US5212939A (en) * | 1991-12-04 | 1993-05-25 | Pratt Jr John M | Marine mooring swivel fitting |
JP2930723B2 (ja) | 1992-11-19 | 1999-08-03 | アンティキャンサー インコーポレーテド | 抗メチオニン化学療法における抗腫瘍薬としてのメチオニナーゼの使用 |
ATE361984T1 (de) | 1992-12-04 | 2007-06-15 | Me Medical Enzymes Ag | Gentechnologisch hergestellte glutaminase und ihre verwendung in therapie |
DK75593D0 (es) | 1993-06-25 | 1993-06-25 | Novo Nordisk As | |
GB9418092D0 (en) * | 1994-09-08 | 1994-10-26 | Red Cross Found Cent Lab Blood | Organic compounds |
KR0164757B1 (ko) * | 1995-06-13 | 1999-01-15 | 김광호 | 공조장치의 살균집진장치와 그 방법 |
DE69638117D1 (de) | 1995-09-21 | 2010-03-04 | Genentech Inc | Varianten des menschlichen Wachstumshormons |
CU22585A1 (es) | 1995-11-17 | 1999-11-03 | Centro Inmunologia Molecular | Anticuerpos monoclonales antiidiótipos (ab2) de tipo igg con alta conectividad idiotípica y composiciones farmacéuticas que los contienen. su uso como inmunoreguladores de la respuesta inmune. |
US6548644B1 (en) | 1997-03-10 | 2003-04-15 | Immunex Corporation | Site protected protein modification |
US6183738B1 (en) | 1997-05-12 | 2001-02-06 | Phoenix Pharamacologics, Inc. | Modified arginine deiminase |
US5981239A (en) | 1997-09-24 | 1999-11-09 | Great Lakes Chemical Corp. | Synthesis of optically active phenylalanine analogs using Rhodotorula graminis |
US6451986B1 (en) | 1998-06-22 | 2002-09-17 | Immunex Corporation | Site specific protein modification |
US6461849B1 (en) | 1998-10-13 | 2002-10-08 | Novozymes, A/S | Modified polypeptide |
US6686164B1 (en) | 1998-10-30 | 2004-02-03 | Novozymes A/S | Low allergenic protein variants |
JP4812167B2 (ja) | 1999-02-12 | 2011-11-09 | モレキュラー インサイト ファーマスーティカルズ インコーポレイテッド | 薬物輸送用マトリックス、ならびにその作成方法および使用方法 |
US6586398B1 (en) | 2000-04-07 | 2003-07-01 | Amgen, Inc. | Chemically modified novel erythropoietin stimulating protein compositions and methods |
WO2001079469A2 (en) | 2000-04-14 | 2001-10-25 | University Of South Carolina Research Foundation | Cloning of corynebacteriaceae histidine ammonia lyase and therapeutic uses |
US6967097B2 (en) | 2000-07-24 | 2005-11-22 | Pcbu Services, Inc. | Phenylalainine ammonia lyase polypeptide and polynucleotide sequences and methods of obtaining and using same |
US6939941B2 (en) * | 2001-09-12 | 2005-09-06 | Toray Fine Chemicals Co., Ltd. | Preparation of polysulfide compositions |
IL162811A0 (en) | 2002-02-26 | 2005-11-20 | Du Pont | Method for the recombination of genetic elements |
US20080124275A1 (en) | 2002-11-14 | 2008-05-29 | The Scripps Research Institute | Crystalline Form of Fatty Acid Amide Hydrolase (Faah) |
JP2008513027A (ja) | 2004-09-17 | 2008-05-01 | バイオマリン ファーマシューティカル インコーポレイテッド | フェニルアラニンアンモニアーリアーゼの改変体および化学的に修飾された改変体 |
CA2614769A1 (en) * | 2005-03-10 | 2006-09-21 | Verenium Corporation | Lyase enzymes, nucleic acids encoding them and methods for making and using them |
US7534595B2 (en) * | 2006-06-12 | 2009-05-19 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof |
US7531341B1 (en) | 2006-06-12 | 2009-05-12 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof |
DE102006032167B4 (de) | 2006-07-12 | 2014-11-27 | Evonik Degussa Gmbh | Verfahren zur Herstellung von Triallylisocyanurat (TAIC) |
US20090011400A1 (en) | 2006-12-01 | 2009-01-08 | The Salk Institute for Biological Studies and The Regents of the University of California | Substrate switched ammonia lyases and mutases |
US7537923B2 (en) | 2007-08-17 | 2009-05-26 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof |
WO2010014225A2 (en) | 2008-07-30 | 2010-02-04 | Biomarin Pharmaceutical Inc. | Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase |
-
2008
- 2008-04-22 US US12/107,736 patent/US7537923B2/en active Active
- 2008-04-22 US US12/107,731 patent/US7560263B2/en active Active
- 2008-08-14 CL CL2008002390A patent/CL2008002390A1/es unknown
- 2008-08-15 ES ES08795357.6T patent/ES2602618T3/es active Active
- 2008-08-15 HU HUE08795357A patent/HUE029510T4/en unknown
- 2008-08-15 PT PT87953576T patent/PT2175875T/pt unknown
- 2008-08-15 JP JP2010521043A patent/JP5584120B2/ja active Active
- 2008-08-15 SI SI200831703A patent/SI2175875T1/sl unknown
- 2008-08-15 PE PE2008001395A patent/PE20090605A1/es active IP Right Grant
- 2008-08-15 DK DK08795357.6T patent/DK2175875T3/en active
- 2008-08-15 EP EP08795357.6A patent/EP2175875B1/en active Active
- 2008-08-15 MX MX2009012261A patent/MX2009012261A/es active IP Right Grant
- 2008-08-15 WO PCT/US2008/009765 patent/WO2009025760A2/en active Application Filing
- 2008-08-15 RU RU2009141987/15A patent/RU2009141987A/ru not_active Application Discontinuation
- 2008-08-15 AR ARP080103596A patent/AR067972A1/es not_active Application Discontinuation
- 2008-08-15 BR BR122018072594A patent/BR122018072594B8/pt active IP Right Grant
- 2008-08-15 RU RU2012134838/15A patent/RU2553343C2/ru active
- 2008-08-15 CN CN200880016488.XA patent/CN101803492B/zh active Active
- 2008-08-15 CA CA2687028A patent/CA2687028C/en active Active
- 2008-08-15 LT LTEP08795357.6T patent/LT2175875T/lt unknown
- 2008-08-15 PL PL08795357T patent/PL2175875T3/pl unknown
- 2008-08-15 TW TW097131325A patent/TWI418787B/zh active
- 2008-08-15 BR BRPI0811589A patent/BRPI0811589B8/pt active IP Right Grant
- 2008-08-15 AU AU2008289549A patent/AU2008289549B2/en active Active
-
2009
- 2009-04-09 US US12/421,557 patent/US7790433B2/en active Active
-
2010
- 2010-07-09 US US12/833,911 patent/US20100278802A1/en not_active Abandoned
-
2016
- 2016-11-08 HR HRP20161474TT patent/HRP20161474T1/hr unknown
- 2016-11-10 CY CY20161101163T patent/CY1118222T1/el unknown
-
2019
- 2019-01-24 AR ARP190100158A patent/AR117389A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20090605A1 (es) | Composiciones de fenilalanina amoniaco-liasa procariotica y metodos del tratamiento del cancer usando composiciones de la misma | |
CL2011000653A1 (es) | Compuestos derivados del acido 1-amino-2-ciclobutil-etil-boronico; composicion farmaceutica; polvo liofilizado y metodo para obtenerlo; y uso en el tratamiento del cancer. | |
DE602005021770D1 (de) | Indol-1-yl-essigsäurederivate | |
PE20090315A1 (es) | Composiciones de fenilalanina amoniaco liasa procariotica y metodos para usar composiciones de la misma | |
ECSP055671A (es) | Nuevas quinazolinonas espirocondensadas y su uso como inhibidores de la fosfodiesteresa | |
WO2010084115A3 (en) | Antiviral agents | |
CL2008000690A1 (es) | Compuestos derivados del acido indol-3-propionico; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hiperlipidemia, hipertension; entre otras. | |
PE20130198A1 (es) | Composiciones solidas | |
PA8576201A1 (es) | Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco | |
AR047928A1 (es) | Derivados de tetrahidropiridoindol | |
EA200700976A1 (ru) | Соединения в виде молекул-конъюгатов, обладающих повышенной активностью в отношении включения клеткой | |
CY1107342T1 (el) | Χρηση παραγωγων νιτριλιου ως φαρμακο | |
CL2007002689A1 (es) | Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras. | |
MX2013008478A (es) | 1, 4 riazepinas/sulfonas como inhibidores de beta secretasa 1 (base1) y/o beta secretasa 2 (bace2). | |
RU2016135039A (ru) | Композиция для обработки поверхностных дефектов | |
BR112013028679A2 (pt) | inibidores do vírus da hepatite c | |
TW200626527A (en) | Novel hexafluoroisopropanol derivatives | |
MX2012005689A (es) | Analogos de acido araquidonico y metodos para el tratamiento analgesico utilizando los mismos. | |
MX2012007225A (es) | Composicion farmaceutica que comprende mezcla de solventes y derivado o analogo de vitamina d. | |
PH12015501122A1 (en) | Flowable peroxide containing oral care compositions | |
AR057648A1 (es) | Composicion de metaflumizona para la administracion topica | |
BRPI0408299A (pt) | inibidores de catepsina s | |
BRPI0621347B8 (pt) | composição farmacêutica para aumentar a produção de eritrócitos e para o tratamento de anemia | |
CO7170181A2 (es) | Nueva composición de alfentanilo para el tratamiento del dolor agudo | |
EA200700023A1 (ru) | Разрыхляющаяся при пероральном приёме фармацевтическая композиция, содержащая рисперидон |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |